136 related articles for article (PubMed ID: 7884419)
1. Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphoma.
Younes A; Sarris A; Melnyk A; Romaguera J; McLaughlin P; Swan F; Rodriguez MA; Hagemeister F; Moore D; North L
J Clin Oncol; 1995 Mar; 13(3):583-7. PubMed ID: 7884419
[TBL] [Abstract][Full Text] [Related]
2. No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule.
Younes A; Ayoub JP; Hagemeister FB; McLaughlin P; Sarris A; Rodriguez MA; Swan F; Romaguera JE; Martin J; Cabanillas F
J Clin Oncol; 1996 Feb; 14(2):543-8. PubMed ID: 8636769
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of 3-hour infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte.
Casasnovas RO; Haioun C; Dumontet C; Gabarre J; Richard B; Lederlin P; Caillot D; Stamatoullas A; Morel P; Quesnel B; Blay JY; Bouabdallah K; Gisselbrecht C
Haematologica; 2000 May; 85(5):502-7. PubMed ID: 10800167
[TBL] [Abstract][Full Text] [Related]
4. Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma.
Sarris AH; Younes A; McLaughlin P; Moore D; Hagemeister F; Swan F; Rodriguez MA; Romaguera J; North L; Mansfield P; Callendar D; Mesina O; Cabanillas F
J Clin Oncol; 1996 Jan; 14(1):233-9. PubMed ID: 8558203
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel activity for the treatment of non-Hodgkin's lymphoma: final report of a phase II trial.
Younes A; Ayoub JP; Sarris A; Hagemeister F; North L; Pate O; McLaughlin P; Rodriguez MA; Romaguera J; Kurzrock R; Preti A; Bachier C; Smith T; Cabanillas F
Br J Haematol; 1997 Feb; 96(2):328-32. PubMed ID: 9029021
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group trial 9246.
Press OW; LeBlanc M; O'Rourke TJ; Gagnet S; Chapman RA; Balcerzak SP; Fisher RI
J Clin Oncol; 1998 Feb; 16(2):574-8. PubMed ID: 9469343
[TBL] [Abstract][Full Text] [Related]
8. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with paclitaxel for recurrent primary brain tumors.
Chamberlain MC; Kormanik P
J Clin Oncol; 1995 Aug; 13(8):2066-71. PubMed ID: 7636549
[TBL] [Abstract][Full Text] [Related]
10. Paclitaxel by 3-hour infusion followed by 96-hour infusion on failure in patients with refractory malignant disease.
Chang AY; Boros L; Garrow G; Asbury R
Semin Oncol; 1995 Jun; 22(3 Suppl 6):124-7. PubMed ID: 7597429
[TBL] [Abstract][Full Text] [Related]
11. One-hour paclitaxel infusion schedules: a phase I/II comparative trial.
Greco FA; Hainsworth JD
Semin Oncol; 1995 Jun; 22(3 Suppl 6):118-23. PubMed ID: 7597427
[TBL] [Abstract][Full Text] [Related]
12. Single-agent paclitaxel by 3-hour infusion in the treatment of non-small cell lung cancer: links between p53 and K-ras gene status and chemosensitivity.
Rosell R; González-Larriba JL; Alberola V; Molina F; Monzó M; Benito D; Pérez JM; de Anta JM
Semin Oncol; 1995 Dec; 22(6 Suppl 14):12-8. PubMed ID: 8553077
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel plus high-dose cyclophosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma.
Younes A; Romaguera J; Mesina O; Hagemeister F; Sarris AH; Rodriguez MA; McLaughlin P; Preti HA; Bachier C; Cabanillas F
Br J Haematol; 1998 Dec; 103(3):678-83. PubMed ID: 9858216
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Younes A; Preti HA; Hagemeister FB; McLaughlin P; Romaguera JE; Rodriguez MA; Samuels BI; Palmer JL; Cabanillas F
Ann Oncol; 2001 Jul; 12(7):923-7. PubMed ID: 11521796
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas.
Wilson WH; Chabner BA; Bryant G; Bates S; Fojo A; Regis J; Jaffe ES; Steinberg SM; Goldspiel BR; Cheson BD
J Clin Oncol; 1995 Feb; 13(2):381-6. PubMed ID: 7531220
[TBL] [Abstract][Full Text] [Related]
17. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion.
Eisenhauer EA; ten Bokkel Huinink WW; Swenerton KD; Gianni L; Myles J; van der Burg ME; Kerr I; Vermorken JB; Buser K; Colombo N
J Clin Oncol; 1994 Dec; 12(12):2654-66. PubMed ID: 7989941
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.
Murphy WK; Fossella FV; Winn RJ; Shin DM; Hynes HE; Gross HM; Davilla E; Leimert J; Dhingra H; Raber MN
J Natl Cancer Inst; 1993 Mar; 85(5):384-8. PubMed ID: 8094466
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer.
Hainsworth JD; Thompson DS; Greco FA
J Clin Oncol; 1995 Jul; 13(7):1609-14. PubMed ID: 7602349
[TBL] [Abstract][Full Text] [Related]
20. A phase I trial of 3-hour infusions of paclitaxel (Taxol) with or without granulocyte colony-stimulating factor.
Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
Semin Oncol; 1994 Oct; 21(5 Suppl 8):9-14. PubMed ID: 7524159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]